文献速递前列腺癌

RNA原位杂交检测尿液中前列腺癌细胞

Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization.
PubMed 文献 · J Urol · 2021-02-22

本研究开发了一种靶向NKX3-1、PRAC1和PCA3的多重RNA原位杂交检测方法,用于检测尿液中脱落的 prostate 细胞。在98例疑似前列腺癌患者中,该检测对临床显著前列腺癌的敏感性为51%,特异性为95%,且阳性结果与中高危癌症、PSA密度、显著疾病和Gleason评分显著相关。

要点

  • 尿液RNA原位杂交检测前列腺癌特异性高(95%),敏感性中等(51%)。
  • 阳性结果与临床显著前列腺癌及Gleason评分显著相关。
  • 该检测有望用于前列腺癌无创诊断和监测。

核心结论

  • 通过RNA原位杂交识别尿液中脱落的前列腺癌细胞,为前列腺癌提供了一种高特异性、无创的检测工具。

研究设计与样本

  • 前瞻性队列研究,纳入98例疑似前列腺癌患者,直肠指检后收集尿液,分离沉渣并进行RNA原位杂交检测。

主要发现

  • 69份样本检测到前列腺细胞(NKX3-1/PRAC1+),其中20份PCA3阳性(即检出前列腺癌细胞)。
  • RNA原位杂交阳性与中/高危癌症(p=0.003)、PSA密度(p=0.022)、显著疾病(p<0.0001)和Gleason评分(p=0.003)显著相关。
  • 该检测对临床显著前列腺癌的敏感性为51%,特异性为95%。

关键数值与推荐

  • 前列腺细胞定义为NKX3-1和/或PRAC1阳性,前列腺癌细胞定义为PCA3阳性。

临床怎么用

  • 该尿液检测可作为疑似前列腺癌患者的无创辅助诊断工具,高特异性有助于确认临床显著前列腺癌。

局限性

  • 样本量较小(98例),敏感性中等(51%),需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Noninvasive tests that can accurately detect prostate cancer are urgently needed for prostate cancer diagnosis, surveillance and prognosis. Exfoliated prostate cells captured in urine represent a promising resource for noninvasive detection of prostate cancer. We investigated performance of a novel cell-based urine test for detection of clinically significant prostate cancer. MATERIALS AND METHODS: We previously developed a multiplex RNA in situ hybridization assay targeting NKX3-1, PRAC1 and PCA3 that enables identification and quantification of malignant and benign prostate cells released into urine. We investigated application of the assay for prostate cancer detection in a cohort of 98 patients suspected of harboring prostate cancer. Urine was collected following digital rectal examination, and the sediment was isolated and evaluated by RNA in situ hybridization. Samples were scored based on cellular expression of RNA in situ hybridization targets. Cells of prostate origin were defined by positivity for NKX3-1 and/or PRAC1, and prostate cancer cells by positivity for PCA3. RESULTS: Prostate cells (NKX3-1/PRAC1+ cells) were detected in 69 samples, among which 20 were positive for PCA3 (ie positive for prostate cancer cells). Comparison of RNA in situ hybridization results with biopsy outcome and clinical variables revealed that positivity for cancer by RNA in situ hybridization significantly correlated with intermediate/high risk cancer (p=0.003), PSA density (p=0.022), significant disease (p <0.0001) and Gleason score (p=0.003). The test was 95% specific and 51% sensitive for detection of clinically significant prostate cancer. CONCLUSIONS: Identification of exfoliated prostate cancer cells in urine by RNA in situ hybridization provides a novel tool for highly specific and noninvasive detection of prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Eskra JN, Rabizadeh D, Zhang J, et al. Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization. J Urol. 2021. PMID: 33617332. doi:10.1097/JU.0000000000001691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。